Biotricity is trading 6.95% down at $0.11, with no clearly reported company-specific catalyst for August 25, 2026.
- On August 18, the company filed a Form 12b-25 notice concerning a delayed quarterly report and said it expected to file within five calendar days.
- Biotricity anticipated no significant year-over-year operating-results change. Broader markets are higher, so the decline does not align with the provided market trend.